Cassava Sciences said that its drug did not significantly reduce cognitive decline in 1,900 people with mild to moderate ...

Today’s column will focus primarily on two lists, the first being a list of early signs and symptoms of dementia that ...

APOE4 carriers had higher blood-brain barrier permeability, even without cognitive decline or amyloid beta buildup, ...

The active agent in the nasal spray, 2-bromopalmitate, carries a high risk of interfering with a number of processes, making ...

Alector’s AbbVie-partnered Alzheimer's asset has failed to slow disease progression in a phase 2 study, the latest in a ...

To determine the diagnostic accuracy of the results of CSF tests compared to the gold standard PET imaging, the Munich researchers evaluated the data of over 400 patients with suspected Alzheimer's ...

(Reuters) -Cassava Sciences said it will stop all trials of its Alzheimer's disease drug after it failed a late-stage study, ...

While everyone gears up for one of the busiest travel times of the year, the Alzheimer’s Foundation of America is offering ...

Researchers have uncovered how certain genetic mutations lead to unique spherical amyloid plaques in inherited forms of ...

Cassava Sciences' troubled development of Alzheimer's disease candidate simufilam looks like it may have finally reached the ...

The Cassava Sciences story ended Monday exactly as many knew it would — with the company’s experimental drug for Alzheimer’s ...

Alector Therapeutics, working with AbbVie, was testing whether modulating immune cells in brain would slow Alzheimer's ...